Ultima Genomics Sequencer for Single-Cell RNA-Seq Evaluated
|
By LabMedica International staff writers Posted on 19 Sep 2022 |

Single-cell RNA sequencing (scRNA-seq) enables the study and characterization of cellular states and pathways at ever-growing investigational scales, including the Human Cell Atlas, cell atlases for tumors and other diseases, and large-scale Perturb-Seq screens of millions of cells under genetic or drug perturbations.
Mostly natural sequencing-by-synthesis (mnSBS) is a new sequencing chemistry that relies on a low fraction of labeled nucleotides, combining the efficiency of non-terminating chemistry with the throughput and scalability of optical endpoint scanning within an open fluidics system to enable high-throughput sequencing.
Genomic Scientists at the Broad Institute (Cambridge, MA, USA) and their colleagues devised a library preparation method to run single-cell libraries generated with 10x Genomics' Chromium platform (Pleasanton, CA , USA) on the Ultima Genomics UG100 instrument (Newark, CA, USA), which produces single-end, rather than paired-end, reads. The method uses a PCR-based kit to convert the 10x libraries, which are designed to run on Illumina sequencers (Illumina, San Diego, CA, USA), for use with the Ultima sequencer.
The scientists demonstrated successful application in four scRNA-seq case studies of different technical and biological types, including 5′ and 3′ scRNA-seq, human peripheral blood mononuclear cells (PBMC) from a single individual and in multiplex, as well as Perturb-Seq. Benchmarking shows that results from mnSBS-based scRNA-seq are very similar to those using Illumina sequencing, with minor differences in results related to the position of reads relative to annotated gene boundaries, owing to single-end reads of Ultima being closer to gene ends than reads from Illumina.
Of the 166 genes with differences in expression for 3′ PBMC between the two sequencing platforms, most (130 genes, 78.3%) differed in the fraction of reads that were assigned by Cell Ranger to the gene out of all the reads mapped to that gene region. This suggests that this is related to how single- and paired-end reads map to different locations relative to the transcript. Ultima reads map closer to the 5′ and 3' end than do Illumina reads. Because Cell Ranger excludes reads that do not fully map within annotated gene boundaries, more Ultima reads are excluded from analysis as they are closer to gene ends. This difference in location can also lead to more multimapping or ambiguous reads.
Gilad Almogy, PhD, Ultima CEO and Cofounder, said, “The UG100 is a generic sequencing platform and is capable of accommodating most existing sequencing libraries, including libraries prepared for other platforms via a simple conversion process. Specifically, we've successfully tested sequencing of 10x single cell ATAC-seq and CITE-seq libraries, as well as other single-cell labeling approaches.”
Joshua Levin, PhD, a senior author of the study, said , “Given that it would be a lower cost, other issues would not be a problem that would prevent you from using Ultima, and that for some applications, such as T- and B-cell receptor sequencing, 5' approaches are required. Ultima has claimed it can deliver NGS of equivalent accuracy to Illumina at approximately USD 1 per Gb, compared to approximately USD 6 to USD 7 per Gb, list price, for Illumina's highest throughput NovaSeq instrument. You can change the scale of your screen.”
The authors concluded that the method was compatible with state-of-the-art scRNA-seq libraries independent of the sequencing technology. They expect mnSBS to be of particular utility for cost-effective large-scale scRNA-seq projects. The study was published on September 15, 2022 in the journal Nature Biotechnology.
Related Links:
Broad Institute
10x Genomics
Ultima Genomics
Illumina
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







